Abstract

The present invention relates to a composition comprising L-aspartic acid as an active ingredient for promoting differentiation into myocytes or osteoblasts. It has been confirmed that L-aspartic acid regulates the expression of muscle differentiation markers, inhibits muscle atrophy, and regulates the expression of differentiation markers of osteoblasts, and thus can be advantageously used for preventing, treating, and alleviating muscle diseases, osteogenesis, or diseases requiring promotion of osteogenesis.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
• A61P 19/00 - Drugs for skeletal disorders

Goods & Services

RNA interference technology research; drug discovery services; pharmaceutical research and development; scientific research in the field of pharmacy; technical research in the field of pharmaceutical studies; pharmaceutical drug development services; providing information on the testing, inspection and research of medical products; clinical trials; laboratory research services relating to dermatology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Goods & Services

RNA interference technology research; drug discovery services; pharmaceutical research and development; scientific research in the field of pharmacy; technical research in the field of pharmaceutical studies; pharmaceutical drug development services; providing information on the testing, inspection and research of medical products; clinical trials; laboratory research services relating to dermatology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Abstract

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a function of PHF20 (PHD finger protein 20) in a myogenic differentiation mechanism and, more particularly, to a use of a PHF20 gene expression inhibitor or a PHF20 protein activity inhibitor. The PHF20 gene expression inhibitor or the PHF20 protein activity inhibitor according to the present invention promotes muscle differentiation in vitro and in vivo, and thus can be utilized in various ways in the field of prevention, improvement or treatment of diseases caused by muscle loss.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/13 - Nucleic acids or derivatives thereof
• A23K 20/153 - Nucleic acidsHydrolysis products or derivatives thereof

Abstract

The present invention relates to a function of PHF20 (PHD finger protein 20) in a muscle differentiation mechanism and, more particularly, to a use of a PHF20 gene expression inhibitor or a PHF20 protein activity inhibitor. The PHF20 gene expression inhibitor or the PHF20 protein activity inhibitor according to the present invention promotes muscle differentiation in vitro and in vivo, and thus can be utilized in various ways in the field of prevention, improvement or treatment of diseases caused by muscle loss.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A23L 33/13 - Nucleic acids or derivatives thereof
• A23K 20/153 - Nucleic acidsHydrolysis products or derivatives thereof